138 related articles for article (PubMed ID: 14704863)
1. Genetics of diabetic cardiovascular disease: identification of a major susceptibility gene.
Levy AP
Acta Diabetol; 2003 Dec; 40 Suppl 2():S330-3. PubMed ID: 14704863
[TBL] [Abstract][Full Text] [Related]
2. Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease.
Levy AP
Isr Med Assoc J; 2004 May; 6(5):308-10. PubMed ID: 15151377
[No Abstract] [Full Text] [Related]
3. Effects of glycaemic control on cardiovascular disease in diabetic American Indians: the Strong Heart Study.
Lu WQ; Resnick HE; Jablonski KA; Jain AK; Jones KL; Robbins DC; Howard BV
Diabet Med; 2004 Apr; 21(4):311-7. PubMed ID: 15049931
[TBL] [Abstract][Full Text] [Related]
4. Hypothesis--haptoglobin genotype and diabetic nephropathy.
Nakhoul FM; Miller-Lotan R; Awaad H; Asleh R; Levy AP
Nat Clin Pract Nephrol; 2007 Jun; 3(6):339-44. PubMed ID: 17525716
[TBL] [Abstract][Full Text] [Related]
5. Genetic susceptibility to macrovascular complications of type 2 diabetes mellitus.
Barakat K; Hitman GA
Best Pract Res Clin Endocrinol Metab; 2001 Sep; 15(3):359-70. PubMed ID: 11554776
[TBL] [Abstract][Full Text] [Related]
6. Haptoglobin phenotype and vascular complications in patients with diabetes.
Levy AP; Roguin A; Hochberg I; Herer P; Marsh S; Nakhoul FM; Skorecki K
N Engl J Med; 2000 Sep; 343(13):969-70. PubMed ID: 11012324
[No Abstract] [Full Text] [Related]
7. Relation of haptoglobin phenotype to early vascular changes in patients with diabetes mellitus.
Shor M; Boaz M; Gavish D; Wainshtein J; Matas Z; Shargorodsky M
Am J Cardiol; 2007 Dec; 100(12):1767-70. PubMed ID: 18082523
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E.
Levy AP; Blum S
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1105-11. PubMed ID: 18035926
[TBL] [Abstract][Full Text] [Related]
9. Haptoglobin genotype and its role in diabetic cardiovascular disease.
Costacou T; Levy AP
J Cardiovasc Transl Res; 2012 Aug; 5(4):423-35. PubMed ID: 22447230
[TBL] [Abstract][Full Text] [Related]
10. Haptoglobin phenotype as a predictive factor of mortality in diabetic haemodialysis patients.
Burbea Z; Nakhoul F; Zoabi R; Hochberg I; Levy NS; Benchetrit S; Weissgarten J; Tovbin D; Knecht A; Iaina A; Herman M; Kristal B; Levy AP
Ann Clin Biochem; 2004 Nov; 41(Pt 6):469-73. PubMed ID: 15588436
[TBL] [Abstract][Full Text] [Related]
11. Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus.
Miller-Lotan R; Herskowitz Y; Kalet-Litman S; Nakhoul F; Aronson D; Zoabi R; Asaf R; Ben-Izhak O; Sabo E; Lim SK; Baumann H; Berger FG; Levy AP
Diabetes Metab Res Rev; 2005; 21(4):332-7. PubMed ID: 15852445
[TBL] [Abstract][Full Text] [Related]
12. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study.
Levy AP; Hochberg I; Jablonski K; Resnick HE; Lee ET; Best L; Howard BV;
J Am Coll Cardiol; 2002 Dec; 40(11):1984-90. PubMed ID: 12475459
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease.
Asleh R; Levy AP
Vasc Health Risk Manag; 2005; 1(1):19-28. PubMed ID: 17319095
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic control modifies the haptoglobin 2 allele-conferred susceptibility to coronary artery disease in Type 1 diabetes.
Costacou T; Evans RW; Orchard TJ
Diabet Med; 2016 Nov; 33(11):1524-1527. PubMed ID: 27028131
[TBL] [Abstract][Full Text] [Related]
15. Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy.
Levy AP
Pharmacol Ther; 2006 Nov; 112(2):501-12. PubMed ID: 16854468
[TBL] [Abstract][Full Text] [Related]
16. The Diamant Alpin Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients.
Pernod G; Bosson JL; Golshayan D; Barro C; Alloatti S; Turc-Baron C; Quarello F; Jeantet A; Von Albertini B; Forêt M; Lauren G; Cordonnier D; Piccoli G; Wauters JP;
J Nephrol; 2004; 17(1):66-75. PubMed ID: 15151261
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants predisposing to cardiovascular disease.
Visvikis-Siest S; Marteau JB
Curr Opin Lipidol; 2006 Apr; 17(2):139-51. PubMed ID: 16531750
[TBL] [Abstract][Full Text] [Related]
18. Haptoglobin phenotype and coronary artery collaterals in diabetic patients.
Hochberg I; Roguin A; Nikolsky E; Chanderashekhar PV; Cohen S; Levy AP
Atherosclerosis; 2002 Apr; 161(2):441-6. PubMed ID: 11888529
[TBL] [Abstract][Full Text] [Related]
19. SAGE programs: model-free linkage analysis for complex cardiovascular phenotypes.
Rao S; Wang QK
Methods Mol Med; 2006; 128():61-89. PubMed ID: 17071990
[TBL] [Abstract][Full Text] [Related]
20. [Type 2 diabetes mellitus and cardiovascular diseases: evaluation, treatment and prevention strategies].
Mosseri MM; Fisman EZ; Tenenbaum A
Harefuah; 2006 Feb; 145(2):141-6, 164. PubMed ID: 16509421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
